tbuckley/cabot-search huggingface dataset:
Face
Authors: Melvyn H. Schreiber
Journal: JAMA (1982)

A few minutes between patients. Time to wash my hands and splash a little water on my face. My face. Crow's-feet at my eyes... turkey wattles at my neck. And what has become of my hair? I don't remember growing older... My face has more character now than when I was a boy. A boy with smooth skin, a tight chin, something of a pompadour. I've seen pictures of him, and I wonder why he seems a stranger to me. I recognize his eyes; they seem to have changed the least, though now they are surrounded by wrinkles, graying eyebrows, and bifocal lenses. The forehead is not mine—not enough skin and brown spots to be mine. Look at those lips: full and sensual then, thinner now, and less easily amused. I barely remember what he was like... him with his innocence, his ambition to be good. Do justly, love mercy,
HYPERCALCEMIA AND RENAL INJURY
Authors: J. E. H.
Journal: Annals of Internal Medicine (1942)

Editorial1 January 1942HYPERCALCEMIA AND RENAL INJURYJ. E. H.J. E. H.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-16-1-176 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt is well known that with skeletal immobilization there occurs bone rarefaction. It is also well known that a considerable portion of the lime salts exported from the body in this process are handled by the kidneys. The excess excretion of calcium in the urine, or hypercalciuria, is presumably the reason for the frequency of urinary tract stones in patients with healing fractures, an association which has been observed for many years.That hypercalcemia can be a direct result of the rapid mobilization of lime salts during the development of atrophy of disuse has only very recently been suggested. Two...1 ORR WJ: Personal communication—to be published. Google Scholar2 WILKINS L: Personal communication. Google Scholar3 ALBRIGHTBURNETTCOPEPARSON FCHOW: Acute atrophy of bone (osteoporosis) simulating hyperparathyroidism, Jr. Clin. Endocrinology, 1941, i, 711. CrossrefGoogle Scholar4 BUTLER AM: Personal communication-to be published. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byImmobilisation hypercalcaemia complicating polyneuropathy in adolescent boys.Some Extrarenal Diseases Associated with Renal Stone or NephrocalcinosisEffect of phosphate supplementation during immobilization of normal menNiere bei Tumoren, Blutkrankheiten und ParaproteinämienThe Aetiology of osteoporosis: The present positionThe Response of Hypercalcemia in Sarcoidosis to ChloroquineBARBARA J. HUNT, M.B., CH.B., EDMUND REINHOLD YENDT, M.D., F.R.C.P.EMERGENCY POWER AND LIGHTDISUSE OSTEOPOROSISDiagnostic Considerations in HypercalcemiaCURRENT CONCEPTS IN THE MANAGEMENT OF OSTEOPOROSISNewer Concepts of Protein MetabolismDifferentiation of Hyperparathyroidism and the Milk-Alkali (Burnett) SyndromeOsteoporosis, Hypercalcemia and Nephropathy following Immobilization of Children.OsteoporosisHypercalcemia in osteolytic metastatic cancer of the breast 1 January 1942Volume 16, Issue 1Page: 176-178KeywordsAtrophyBoneCalciumExcretionHypercalcemiaKidneysSaltsUrine Issue Published: 1 January 1942 PDF downloadLoading ...
Aspirin and recurrent myocardial infarction
Authors: R. J. Jones
Journal: JAMA (1980)

WITH the recent acceptance by the Food and Drug Administration of controlled clinical trials that establish the safety and efficacy of aspirin for control of transient ischemic attacks in the cerebral circulation and reducing the risk of their progression to stroke,<sup>1,2</sup>one might expect similar protective effects on the coronary circulation. For several years it has been suggested that patients who habitually use aspirin are less liable to have development of myocardial infarction.<sup>3</sup>Three earlier randomized controlled trials<sup>4-6</sup>provided suggestive evidence in support of using aspirin as prophylaxis in coronary heart disease (CHD), but in none did the difference in mortality between the control and experimental groups achieve statistical significance (<i>P</i>&lt;.05). These led to three more trials that have recently seen publication: a trial sponsored by the Medical Research Council (MRC) Epidemiology Unit of South Wales,<sup>7</sup>the Aspirin Myocardial Infarction Study (AMIS) sponsored by the
A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Authors: Rahul Raj Aggarwal, Vivian K. Weinberg, Charles J. Ryan, Andrea Lynne Harzstark, Alan Haruo Bryce, Christina Louise Derleth, Kimberly Lowe, Eric Jay Small
Journal: Journal of Clinical Oncology (2014)

e16060 Background: Cbz/pred extends survival in mCRPC patients (pts) following docetaxel and first-line studies comparing Cbz to docetaxel are ongoing. Mito/pred also has anti-tumor activity in mCRPC and a non-overlapping mechanism of action and toxicity profile with Cbz. A multicenter phase 1 trial was initiated to establish the maximally tolerated dose (MTD) of the combination of Cbz, Mito, and Pred. Methods: Chemotherapy (chemo)-naïve pts with mCRPC were enrolled in an accelerated titration design. The primary objective was to determine the MTD of CAMP; secondary objectives included assessing PSA and objective response rates and duration of response. Starting dose of Cbz was 25 mg/m2 (the currently approved single-agent dose) and Mito 4 mg/m2, administered on day 1 of a 21-day cycle. Mito was escalated by 2 mg/m2 per dose level. Prednisone 5 mg BID and pegfilgrastim were administered with each cycle. Results: 10 pts were enrolled (dose level I, N = 1; dose level II, N = 1; dose level III, N = 4; dose level IV N = 4). The median age was 65 and the median baseline PSA was 76.6. There were 2 DLTs observed at dose level IV (Cbz 25 mg/m2 + mito 10 mg/m2), both grade 4 sepsis. The most common grade ≥ 3 adverse events were hematologic (neutropenia, n = 5; febrile neutropenia, n = 2, thrombocytopenia, n = 2). 2 of 10 pts remain on study, with a median 8.5 of treatment cycles delivered. Maximal PSA declines from baseline > 50% have been observed in 6/10 (60%) of pts. 5 out of 6 evaluable patients with measurable disease have experienced an objective tumor response. Conclusions: The approved single-agent dosage of Mito (12 mg/m2) could not be safely reached in combination with Cbz 25 mg/m2. Pre-planned evaluation of an alternate dosing strategy combining Mito with Cbz 20 mg/m2, which has demonstrated activity in mCRPC and potentially less hematologic toxicity, is underway. Preliminary efficacy data are encouraging but additional follow-up and further study of the treatment combination is required. Clinical trial information: NCT01594918.
Extracorporeal renal transplantation in man
Authors: A. R. Lavender
Journal: JAMA (1968)

The kidney of a 9-year-old child was transplanted extracorporeally to the forearm of a 35-year-old anephric man. The kidney was perfused in a sealed chamber by blood from chronically cannulated forearm vessels. Immunosuppressive drugs and heparin sodium were administered during the transplantation period. Renal function was maintained satisfactorily until acute vascular rejection occurred on the 25th day. There were no untoward signs or symptoms attributable to the procedure, and the patient improved markedly. It is suggested that extracorporeal renal transplantation may be useful as a test for viability and functional competence of cadaver kidneys. It also may be helpful in study of immune rejection mechanisms.
PREPARE FOR THE FOURTH OF JULY.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum for the Research Article: “A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent” by N. Gioelli, F. Maione, C. Camillo, M. Ghitti, D. Valdembri, N. Morello, M. Darche, L. Zentilin, G. Cagnoni, Y. Qiu, M. Giacca, M. Giustetto, M. Paques, I. Cascone, G. Musco, L. Tamagnone, E. Giraudo, G. Serini
Journal: Science Translational Medicine (2018)
Amantadine Hydrochloride
Authors: Albert B. Sabin
Journal: JAMA (1967)

The control of viral respiratory disease by safe and effective drugs is an important research goal, but the usefulness of potential candidates must be evaluated with great care. E. I. Du Pont de Nemours &amp; Company, Wilmington, Del, has recently proposed that amantadine hydrochloride (1-adamantanamine hydrochloride) be used for the prophylaxis of A2 influenza virus disease in human beings. This proposal, based to a large extent on unpublished studies on human beings, led to the present analysis of both the published data and the unpublished reports; the investigators who carried out the studies have given permission to refer to the unpublished data in this communication. <h3>Studies in Tissue Cultures, Eggs, and Experimental Animals</h3><h3>Tissue Culture Studies.—</h3> Investigators<sup>1-3</sup>at the Du Pont laboratories reported that amantadine hydrochloride has an inhibitory effect on the influenza A, Al, and A2 strains that were tested and also on influenza C, the Sendai strain
Saturday
Authors: John Quin
Journal: BMJ (2005)

H ey, Saturday—get up late and it's okay, but not for Henry Perowne, consultant neurosurgeon. Although he is usually “thoughtlessly content” at the weekend, today just happens to coincide with the anti-war demonstration on 15 February 2003. His day starts and ends with a bang. Ian McEwan Jonathan Cape, £17.99, pp 279 ISBN 0 224 07299 4 Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img>![Graphic][4]</img> Perowne is a rationalist, with a boyish enthusiasm for modern science and at odds with the cynicism of these “baffled and fearful” days. Reflecting on trans-sphenoidal hypophysectomy, he considers the procedure “humane and daring—the spirit of benevolence enlivened by the boldness of a high-wire circus act.” A true … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif [4]: /embed/inline-graphic-4.gif
JAMA Reference Directories
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue Access Provided by Korea University Medical Library JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account
Abstract 66: High-dose IgG Completely Inhibited TNF-α-induced, But Not IL-1β-induced, G-CSF Expression By Human Coronary Artery Endothelial Cells
Authors: Akio Matsuda, Kenichiro Motomura, Hirohisa Saito, Kenji Matsumoto, Jun Abe
Journal: Circulation (2015)

High-dose intravenous IgG (IVIG) is a well-established standard therapy for Kawasaki Diseases (KD) that effectively reduces both systemic inflammation and the risk of developing coronary artery aneurysms, in approximately 80% of KD. However, some patients do not respond to IVIG and the cause of their unresponsiveness remains unclear. We previously reported that high-dose IgG specifically and completely inhibited accelerated expression of KD-related cytokines, including G-CSF, by human coronary artery endothelial cells (HCAEC) in response to TNF-α. The suppression of these cytokine genes correlated closely with functional inhibition of a transcription factor, C/EBPδ. Here we show that IL-1β-induced expression of the KD-related cytokines by HCAEC was never inhibited by high-dose IgG treatment. Furthermore, although TNF-α-induced C/EBPδ activities, as measured by gel shift assay, were completely inhibited after high-dose IgG treatment, those induced by IL-1β were not inhibited at all. Our findings suggest that C/EBPδ may play a pivotal role in the clinical effectiveness of IVIG in patients with KD. Greater understanding of the precise underlying mechanisms of IVIG on coronary artery endothelial cells may contribute to the development of novel therapeutic strategies for current IVIG-resistant patients with KD.
Sources of the growth in Medicare physician expenditures
Authors: R. Berenson
Journal: JAMA (1992)

EXPENDITURES for physician services under Part B of Medicare have been rising at rates far exceeding inflation. In the 4-year period from 1985 through 1988, Medicare-allowed charges increased from $19 billion to $27 billion, an annual growth rate of 12.3%. The factors contributing to the high rate of expenditure growth include increases in the number and average age of enrollees, increases in physician fees, and increases in the number and intensity of services. During the 1980s, enrollment growth and other demographic changes consistently accounted for about 2% of annual Part B growth.<sup>1</sup>From 1980 through 1984, increases in physician fees averaged about 9% per year, while the growth in volume per enrollee was about 7% per year.<sup>2</sup>Congress imposed a fee freeze from July 1984 through April 1986 for all physicians and extended the freeze until January 1987 for nonparticipating physicians. During the period of this policy of
Bicycling—Pro and Con
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Report on Survey Regarding Collection and Use of Cause of Injury Data by States
Journal: JAMA (1998)

In October 1997, the Injury Control and Emergency Health Services Section of the American Public Health Association (APHA) conducted a survey of all 50 states, the District of Columbia (DC), and Puerto Rico to assess the availability of external cause-of-injury data in statewide hospital discharge data systems (HDDS), hospital emergency department data systems (HEDDS), and other ambulatory care data systems. The report on the findings of the analysis, How States are Collecting and Using Cause of Injury Data, includes recommendations for improving the quality and availability of statewide injury-related data for injury-prevention activities.
Hypertensive Retinopathy
Authors: Tien Y. Wong, Paul Mitchell
Journal: New England Journal of Medicine (2004)

This review explains the pathophysiological changes that elevated blood pressure produces in the retinal circulation. Recent studies show that some specific retinal signs are strong predictors of stroke, independent of elevated blood pressure. Identifying the degree of retinopathy can help clinicians to deliver optimal treatment and prevent cardiovascular disease and death.
A GENERAL WITH PRONOUNCED SANITARY IDEAS.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ANOTHER STATE SOCIETY JOURNAL.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE DIETETIC DIFFERENCES BETWEEN LIGHT AND DARK MEAT.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Multistage Models of Carcinogenesis
Authors: P. Armitage
Journal: Environmental Health Perspectives (1985)

The simple multistage model of carcinogenesis is outlined. It provides a satisfactory explanation of the power law for the age incidence of many forms of epithelial carcinoma, for the effects in human populations of changing exposures to supposed carcinogenic agents, and for many of the observed effects of applied carcinogens in animal experiments. In particular, the evidence on the effects of starting and stopping cigarette smoking suggests that both an early and a late stage may be affected. In the absence of direct evidence on the nature of the cellular changes there is some reluctance to accept a model with more than two stages, and several forms of two-stage models provide good general explanations of observed phenomena. Such a model has recently been applied to breast cancer; another approach to this disease, effectively involving transformations of the time scale, is discussed.
Urinary White-Cell Excretion Under T.A.B. Vaccine Provocation
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal